FOLFOX in pancreatic G1 and G2 neuroendocrine tumors

#3606

Introduction: Aim of this study: The chemotherapy of metastatic pancreatic neuroendocrine tumors (TNEm) of low grade (G1, G2 Ki-67< 20%) is based on old studies and relies on streptozocin, the tolerance of which is poor. We wanted to evaluate the efficacy of the combination 5 FU + oxaliplatin (FOLFOX) in patients with TNEp.

Aim(s): Chemotherapy with FOLFOX is interesting antitumor activity in well-differentiated neuroendocrine tumors, without major toxicity.

Materials and methods: Retrospective multicenter study of 16 cases of TNEm treated between April 2018 and August 2022, after proposal in MDT NET. All had radiologically progressive disease at baseline. The following were evaluated: Response according to RECIST 1.0, progression-free survival and overall survival compared to D0 of chemotherapy, evolution of symptoms (general condition, pain, symptoms of tumor hypersecretion) and toxicities.

Conference:

Presenting Author:

Authors: Bengueddache A, Kehili H, Tidjane A, Remini A, Boudjnane N,

Keywords: FOLFOX, metastatic pancreatic neuroendocrine tumor,